An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

This study has been completed.

Study NCT00576173 Information provided by Johnson & Johnson Taiwan Ltd

First Received: December 14, 2007 Last Updated: April 30, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Study Completion Date:	February 2007
Estimated Primary Completion Date:	No date given